Enhancing proteasomal processing improves survival for a peptide vaccine used to treat glioblastoma-Reference-Cited by-同舟云学术

Enhancing proteasomal processing improves survival for a peptide vaccine used to treat glioblastoma

Published:2021-06-16 Issue:598 Volume:13 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Fidanza Mario¹^ORCID,Gupta Puja¹,Sayana Anin¹^ORCID,Shanker Varun²^ORCID,Pahlke Svenja-Maria¹^ORCID,Vu Brandon¹,Krantz Fanny¹,Azameera Aruna¹,Wong Nicollette¹,Anne Navya¹,Xia Yuanxuan³,Rong Jiming¹^ORCID,Anne Avani¹,Skirboll Stephen¹,Lim Michael¹^ORCID,Wong Albert J.¹⁴^ORCID

Affiliation:

1. Department of Neurosurgery, Stanford University Medical Center, Stanford, CA 94305, USA.

2. Department of Bioengineering, California Institute of Technology, Pasadena, CA 91125, USA.

3. Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

4. Cancer Biology Program, Stanford University Medical Center, Stanford, CA 94305, USA.

Abstract

Increasing proteasomal processing efficiency by targeted modification of a peptide vaccine improves survival in a glioblastoma model.

Funder

California Institute for Regenerative Medicine

California Institute of Regenerative Medicine

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference54 articles.

1. Current and future strategies for treatment of glioma

2. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011

3. Malignant Gliomas in Adults

4. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors;Moscatello D. K.;Cancer Res.,1995

5. EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proteasome isoforms in human thymi and mouse models;Immunology Letters;2024-10

2. Sequential Inhibition of PARP and BET as a Rational Therapeutic Strategy for Glioblastoma;Advanced Science;2024-06-19

3. Treatment advances in high-grade gliomas;Frontiers in Oncology;2024-04-10

4. Pharmacological targeting of the tumor–immune symbiosis in glioblastoma;Trends in Pharmacological Sciences;2022-08

5. An unexplored angle: T cell antigen discoveries reveal a marginal contribution of proteasome splicing to the immunogenic MHC class I antigen pool;Proceedings of the National Academy of Sciences;2022-07-08